Insider Selling: Aveanna Healthcare (NASDAQ:AVAH) Insider Sells $97,606.35 in Stock

Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) insider Patrick Cunningham sold 12,759 shares of the business’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $7.65, for a total value of $97,606.35. Following the transaction, the insider owned 374,156 shares in the company, valued at approximately $2,862,293.40. This represents a 3.30% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Aveanna Healthcare Price Performance

AVAH stock opened at $7.34 on Friday. The firm has a market cap of $1.53 billion, a P/E ratio of 20.39 and a beta of 2.06. The company has a debt-to-equity ratio of 140.39, a quick ratio of 1.23 and a current ratio of 1.23. Aveanna Healthcare Holdings Inc. has a 1 year low of $3.67 and a 1 year high of $10.32. The stock has a 50-day simple moving average of $8.45 and a 200-day simple moving average of $8.50.

Key Stories Impacting Aveanna Healthcare

Here are the key news stories impacting Aveanna Healthcare this week:

• Positive Sentiment: Institutional buying in recent quarters — firms including Invesco, Millennium, Zimmer Partners and others increased or established positions in Q4, a vote of confidence that can support the stock over the medium term. MarketBeat Institutional Activity
• Positive Sentiment: Despite recent sales, insiders still retain large, multi‑million‑dollar stakes (CEO, CFO and others remain major shareholders), which can temper panic selling and signal some continued alignment with shareholders. SEC Filing
• Neutral Sentiment: Reported short interest shows zero shares for mid‑February — this is almost certainly a reporting/data anomaly and does not indicate genuine lack of short interest. Treat the short‑interest figure cautiously. Short Interest Data
• Neutral Sentiment: Trading volume today was below recent averages; low volume can amplify price moves when large blocks or news hit the tape (higher intraday volatility risk).
• Neutral Sentiment: Analyst coverage remains mixed: consensus is around a “Hold” with an average target near $11 — helpful context for longer‑term positioning but not an immediate catalyst. Analyst Summary
• Negative Sentiment: Large, concentrated insider selling Feb. 17–19 by CEO Jeff Shaner — roughly 461,900 shares sold across three days (~$3.4M reported proceeds) — is the primary negative catalyst driving downward pressure as the market interprets sizeable CEO disposals as risk reduction. CEO Sales SEC Filing
• Negative Sentiment: Additional senior/executive selling (CFO Matthew Buckhalter, CAO Deborah Stewart, and other insiders including Edwin C. Reisz and Patrick A. Cunningham) involved hundreds of thousands of shares total across the same dates — a reinforcing negative signal that likely amplified the pullback. Other Insider Filings
• Negative Sentiment: Independent coverage singled out the insider selling as the main reason for a recent ~5–6% pullback, increasing market attention on the disposals and reinforcing short‑term selling pressure. AAII Article

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on AVAH. William Blair started coverage on shares of Aveanna Healthcare in a research note on Monday, December 8th. They issued an “outperform” rating for the company. Barclays boosted their price objective on shares of Aveanna Healthcare from $9.00 to $11.00 and gave the stock an “overweight” rating in a report on Friday, January 16th. BMO Capital Markets initiated coverage on Aveanna Healthcare in a research note on Thursday, November 13th. They set an “outperform” rating and a $11.00 target price for the company. UBS Group boosted their price target on Aveanna Healthcare from $9.50 to $10.00 and gave the stock a “neutral” rating in a research note on Thursday, January 15th. Finally, Truist Financial increased their price target on Aveanna Healthcare from $9.50 to $10.00 and gave the company a “hold” rating in a report on Friday, November 7th. Five research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, Aveanna Healthcare currently has an average rating of “Hold” and an average target price of $11.06.

Hedge Funds Weigh In On Aveanna Healthcare

Several large investors have recently modified their holdings of AVAH. Quantbot Technologies LP acquired a new position in Aveanna Healthcare in the second quarter worth about $43,000. MQS Management LLC bought a new position in Aveanna Healthcare during the 2nd quarter worth approximately $59,000. Belvedere Trading LLC acquired a new position in shares of Aveanna Healthcare in the 2nd quarter worth approximately $62,000. Oxford Asset Management LLP bought a new stake in shares of Aveanna Healthcare in the 2nd quarter valued at approximately $64,000. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in shares of Aveanna Healthcare during the 2nd quarter valued at approximately $68,000. Institutional investors own 87.96% of the company’s stock.

About Aveanna Healthcare

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.